Article: [A meta analysis of aidi injection plus taxotere and cisplatin in the treatment of non-small cell lung cancer]

Background: Compared with chemotherapy, whether aidi injection can improve the patient's quality of life is not definite. The aim of this study is to evaluate the efficacy and safety of axotere plus eisplatin chemotherapy combining aidi injection for patients with non-small cell lung cancer (NSCLC).

Methods: We searched relevant randomized controlled trials (RCTs) from Cochrane library, Pubmed, EMBASE, CancerLit, VIP, CBM and CNKI etc. The search was finished in March 20, 2010. We traced the related references and experts in this field, besides we also communicated with other authors to obtain some certain information that has not been found. RCTs of aidi injection plus TP versus TP for advanced NSCLC were included. We evaluated the quality of these included studies and analyzed data by Cochrane Collaboration's RevMan 5.0 software.

Results: Eleven RCTs involving 800 patients were included. meta analysis results suggested that compared with TP chemotherapy alone, the combination had a statistically significant benefit in healing efficacy (RR=1.2, 95%CI: 1.10-1.47, P=0.001) and improving quality of life (QOL) (RR=1.85, 95%Cl: 1.54-2.21, P < 0.001). Besides, the combination also had a statistically significant benefit in myelosuppression, white blood cell (WBC)(RR=0.71, 95%CI: 0.57-0.87, P=0.001) and hematoblast (RR=0.59, 95%CI: 0.40-0.87, P=0.008) and in reducing the gastroenteric reaction (RR=0.75, 95%CI: 0.58-0.98, P=0.03). But the combination had no statistically significant benefit in prevention of reducing hemoglobin (Hb) (RR=0.97, 95%CI: 0.70-1.34, P=0.85), liver function (RR=0.63, 95%CI: 0.09-1.57, P=0.18), kidney function (RR=0.42, 95%CI: 0.14-1.24, P=0.12), peripheral neuritis (RR=0.86, 95%CI: 0.56-1.32, P=0.50), and baldness (RR=0.92, 95%CI: 0.63-1.34, P=0.66).

Conclusions: Compared with TP chemotherapy alone, the combination can significantly improve the efficiency, QOL and myelosuppression, and reduce adverse events.

Citing Articles

Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials.

Xiao Z, Wang C, Li L, Tang X, Li N, Li J Evid Based Complement Alternat Med. 2018; 2018:7918258.

PMID: 29991956 PMC: 6016159. DOI: 10.1155/2018/7918258.

Anti‑metastatic effects of Aidi on human esophageal squamous cell carcinoma by inhibiting epithelial‑mesenchymal transition and angiogenesis.

Shi Q, Diao Y, Jin F, Ding Z Mol Med Rep. 2018; 18(1):131-138.

PMID: 29749455 PMC: 6059661. DOI: 10.3892/mmr.2018.8976.

Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials.

Xiao Z, Wang C, Chen L, Tang X, Li L, Li N Oncotarget. 2016; 8(1):1329-1342.

PMID: 27901493 PMC: 5352058. DOI: 10.18632/oncotarget.13617.

Can Aidi injection restore cellular immunity and improve clinical efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy? A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines.

Xiao Z, Wang C, Sun Y, Li N, Li J, Chen L Medicine (Baltimore). 2016; 95(44):e5210.

PMID: 27858864 PMC: 5591112. DOI: 10.1097/MD.0000000000005210.

Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer.

Zhao H, Zhou H, Wang Y, Chen W, Qi S, Cao J Chin Med J (Engl). 2016; 129(6):723-30.

PMID: 26960377 PMC: 4804420. DOI: 10.4103/0366-6999.178016.

References

1.

Le Chevalier T, Monnier A, Douillard J, Ruffie P, Sun X, Belli L . Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer. 1999; 34(13):2032-6. DOI: 10.1016/s0959-8049(98)00287-1. View

2.

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

3.

Wang D, Chen Y, Ren J, Cai Y, Liu M, Zhan Q . [A randomized clinical study on efficacy of Aidi injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi. 2011; 7(3):247-9. DOI: 10.3779/j.issn.1009-3419.2004.03.16. View

4.

Rivera M . Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med. 2005; 25 Suppl 1:3-10. DOI: 10.1055/s-2004-829639. View

5.

Millward M, Zalcberg J, Bishop J, Webster L, Zimet A, Rischin D . Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997; 15(2):750-8. DOI: 10.1200/JCO.1997.15.2.750. View

[A Meta Analysis of Aidi Injection Plus Taxotere and Cisplatin in the Treatment of Non-small Cell Lung Cancer]